Nanobody-based dual epitopes protein identification (DepID) assay for measuring soluble CD38 in plasma of multiple myeloma patients.

CONCLUSION: We have developed a Nb-based luminescence sandwich assay, named as DepID, for quantification of the soluble CD38 in MM patients' plasma and showed the potency of this method as a tool for general diagnosis of MM or companion diagnosis of the CD38-targeted therapies.
PMID: 29907292 [PubMed - in process]

Source: Analytica Chimica Acta - June 18, 2018 Category: Chemistry Authors: Li T, Li SL, Fang C, Hou YN, Zhang Q, Du X, Lee HC, Zhao YJ Tags: Anal Chim Acta Source Type: research